AVHNY yields 0.88% · JNJ yields 2.13%● Live data
📍 AVHNY pulled ahead of the other in Year 1
Combined, AVHNY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AVHNY + JNJ for your $10,000?
Ackermans & Van Haaren NV engages in the marine engineering and contracting, private banking, real estate and senior care, and energy and resources businesses worldwide. The company operates through five segments: Marine Engineering & Contracting, Private Banking, Real Estate & Senior Care, Energy & Resources, and AvH & Growth Capital. It engages in the marine construction activities, including dredging and civil works on water, as well as offshore activities in the areas of renewable energy, oil and gas, soil and sludge remediation, and aggregate and mineral extraction; real estate development activities; and development of port projects and related industrial zones, as well as offshore wind farms. The company also offers asset management services for various private clients; advisory banking services for entrepreneurs and liberal professionals; and car finance and leasing services through car dealers. In addition, it develops residential and mixed projects; invests in retail and office properties; provides accommodation and care for the elderly; and operates retirement homes. Further, the company produces crude palm oil, rubber, banana, and tea products; manufactures cement; and offers advice, automation, and maintenance services for life science, tank terminal, food and beverage, infrastructure, and chemistry markets. Additionally, it engages in the production and sale of compact biogas installations. Ackermans & Van Haaren NV was founded in 1876 and is headquartered in Antwerp, Belgium.
Full AVHNY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.